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Background: We evaluated stent implantation across stenotic bioprosthetic pulmo-
nary valves in 9 patients.
Methods: Nine patients (6 male patients) underwent stent implantation across
stenotic bioprosthetic pulmonary valves between July 1996 and July 1999 at the
Hospital for Sick Children, Toronto. Catheter intervention was indicated if echo-
cardiography revealed Doppler estimates of right ventricular pressure of more than
two thirds of systemic arterial pressure (or systolic septal flattening with an esti-
mated gradient of 60 mm Hg across the valve prosthesis). Catheterization was
performed during general anesthesia at an age (mean  SD) of 9.3  3.5 years and
a weight of 32.0 17.1 kg 5.9 1.8 years after surgical insertion of a bioprosthetic
valve in the pulmonary position: 7 patients with tetralogy of Fallot, 1 patient with
congenital pulmonary stenosis-insufficiency, and 1 patient after a Rastelli operation.
All had systolic septal flattening and right ventricular dilatation with moderate-to-
severe pulmonary insufficiency before intervention. Fluoroscopy times were 33.1
9.5 minutes. Seven patients received a single P4014 stent, and 2 received single
P308 stents (Palmaz; Johnson & Johnson Interventional Systems, Warren, NJ)
without significant complications.
Results: The right ventricular systemic pressure decreased acutely from 83% 16%
to 41%  10% (P  .001, n  9), and the transvalvular gradient decreased from
49.7  8.5 to 11.0  5.9 mm Hg (P  .001, n  8). During the follow-up period
(10.9  8.1 months, n  8), 1 patient had an unsuccessful attempt at redilation of
the stent (right ventricular pressure, 60% systemic) and underwent uneventful
surgical pulmonary valve replacement. None of the remaining patients had echo-
cardiographic evidence of systolic septal flattening, and right ventricular dimensions
did not change significantly.
Conclusion: Stent implantation is a safe and effective means of providing palliative
relief of obstructed bioprosthetic valves in the pulmonary position and can safely
delay the requirement for pulmonary valve replacement.
Surgical insertion of a bioprosthetic valve to reconstruct the rightventricular (RV) outflow tract has been used in the repair of complexcardiac defects, such as tetralogy of Fallot and transposition of thegreat arteries with ventricular septal defect and pulmonary stenosis.1-3Although such valves tend to perform reasonably well in the pulmo-nary position,4 late stenosis caused by leaflet calcification and size
mismatch as a result of body growth remain universal issues, committing the patient
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to further procedures.5-7 Although surgical valve replace-
ment can be performed at a low mortality risk,3,8 morbidity
is associated with repeat sternotomy and cardiotomy, and
technical difficulties arise from previous operations. Percu-
taneous balloon valvuloplasty has shown only marginal
efficacy for relief of such obstructions.9-14 On the other
hand, in the setting of RV to pulmonary artery conduits, a
significant prolongation of conduit life span has been safely
achieved after implantation of balloon expandable intravas-
cular stents.15-18 In this study we report our experience with
this palliative strategy to relieve obstructions in biopros-
thetic valves in the pulmonary position.
Methods
Study Design
A computer database search identified 9 patients who underwent
placement of intravascular stents across bioprosthetic valves in the
pulmonary position between July 1996 and July 1999 at the
Hospital for Sick Children, Toronto, Ontario, Canada. Data were
compiled retrospectively from the hospital records, including
clinic visits, echocardiograms, catheterizations, and surgical notes.
In particular, the type of valve, diameter, and position were noted.
Informed consent for the procedures was obtained from parents
following guidelines of the Human Subject Protection Committee
of the Hospital for Sick Children, University of Toronto.
Indications for Intervention
Patients with an estimated RV systolic pressure exceeding two
thirds of systemic arterial pressure or a transvalvular gradient of at
least 60 mm Hg, as documented with Doppler echocardiography
(regardless of the presence of symptoms, such as exercise intoler-
ance or fatigue), were referred for catheter intervention.17,18 If no
tricuspid regurgitation was detected on echocardiography, systolic
flattening of the interventricular septum was considered a reliable
indicator of a high (50% systemic) RV systolic pressure.19
Technique
Under general anesthesia, routine right heart hemodynamics and
angiography (right ventricle and main and branch pulmonary ar-
teries) were performed before and after stent implantation. Occa-
sionally, to profile the valve, the lateral image intensifier was
positioned slightly cranial or caudal by using the radiopaque band
on the bioprosthetic valve sewing ring (Figure 1) to adjust the
beam. The minimal valve opening diameter was measured angio-
graphically in the anterior cranial-caudal and lateral views, as was
the length of the main pulmonary artery segment and distance from
the radiopaque ring to the RV muscular cavity. The known diam-
eter of the angiography catheter was used to correct for magnifi-
cation.
The technique of stent delivery has been described in detail
elsewhere.17,18,20 Palmaz stents (Johnson & Johnson Interventional
Systems, Warren, NJ) were used in all patients. In general, a
complex consisting of a long sheath (Mullins type, sizes 8F to 12F;
Cook, Bloomington, Ind), a stent, and a balloon (diameters 12-23
mm, lengths 3-5.5 cm; Mansfield, Boston Scientific, Watertown,
Mass) was advanced percutaneously as a single unit over an
0.035-inch extrastiff guide wire (260-cm length, Amplatz Extra-
Stiff, Cook) to lie across the area of stenosis within the biopros-
thetic valve (usually just above the metallic valvular ring) but still
within the Dacron or pericardial patch extension used for RV
outflow enlargement. Stent diameters (ie, balloon diameters) were
chosen to be 3 or 4 mm less than the rated valve diameter to allow
for the thickness of the sewing ring. As such, the stent was
implanted to have a slight waist (Figure 1). The length of the stent
was chosen to allow the positioning across the sewing ring and
complete apposition against the valve leaflets along the main
pulmonary artery wall. Once the stent was expanded and in a stable
Figure 1. Left panel, Lateral angiogram in the RV outflow tract defining the bioprosthetic valve (*). Valve leaflets
(arrows) were thickened and fused in a semiopened position. Right panel, Immediately after stent implantation
(same projection as in left panel). Note the slight waist in the stent at the valve region (*) and the distance between
the stent and radiopaque sewing ring (usually 3-4 mm).
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position, no further attempts to flare the stent ends were performed.
Prior balloon dilatation of the bioprosthetic valve was performed
in 1 patient without any decrease in RV systolic pressure.
Cefazolin (40 mg/kg per dose; maximum, 1 g) was adminis-
tered intravenously at the time of catheterization and every 8 hours
for a total of 3 doses. Heparin sulfate was administered in the
catheterization laboratory (150 IU/kg; maximum, 5000 IU) and
maintained as a continuous infusion until the following morning
(10 IU  kg1  h1), with no monitoring of the activated partial
thromboplastin time. At discharge, a low dose of aspirin (2-5
mg  kg1  d1; maximum, 325 mg) was prescribed for 3 to 6
months.
Follow-Up
Follow-up visits were at the referring cardiologist’s discretion but
were generally scheduled every 6 months with echocardiographic
evaluation. Repeat catheterization was undertaken if progressive
conduit obstruction with indications for reintervention was sus-
pected from the echocardiographic evaluation.
Statistical Analysis
All values are expressed as means  SD or median and range, as
applicable. A paired Student t test or a Mann-Whitney rank sum
test was used to compare changes in intracardiac pressures and
measurements before the procedure, immediately after, and at
follow-up. Linear regression was used to evaluate the correlation
between pressure gradients (right ventricle to pulmonary artery)
obtained at echocardiography and catheterization. A Fisher exact




Six male and 3 female patients underwent stent placement
across a bioprosthetic valve in the pulmonary position at a
mean age of 9.3 3.5 years (range, 5.9-15.2 years; median,
7.9 years), with a mean weight of 32.0  17.1 kg (range,
14.5-68.2 kg; median, 27.2 kg) and a mean body surface
area of 1.1  0.4 m2 (range, 0.6-1.84 m2; median, 0.98 m2).
Seven patients had repair of tetralogy of Fallot, 1 had a
Rastelli repair for complete transposition of the great arter-
ies with a ventricular septal defect and pulmonary stenosis,
and 1 patient had complete repair of congenital pulmonary
stenosis and insufficiency with closure of an atrial septal
defect and patent arterial duct (Table 1). In 6 patients the
valve implant was in the orthotopic position. The 3 remain-
ing patients had a bioprosthetic pulmonary valve located
within a conduit, 2 having had previous operations that
involved conduits (ie, 1 Rastelli procedure [patient 9] and 1
conduit placed anterior to the native RV outflow tract [pa-
tient 5]). Both of these patients had subsequent operations,
with implantation of a bioprosthetic pulmonary valve within
the conduit. The third patient (patient 2) had a conventional
repair of tetralogy of Fallot with an RV outflow tract patch.
However, because of development of an RV outflow tract
aneurysm, the patient underwent resection of the aneurysm,
and a conduit was placed within the native RV outflow tract,
subsequently undergoing conduit revision and then a valve
implant. A Mitroflow (bovine pericardial) valve (Mitroflow
International, Inc, Richmond, British Columbia, Canada)
was implanted in 8 patients, and a Medtronic Intact (porcine
aortic) valve (Medtronic, Minneapolis, Minn) was im-
planted in 1 patient. The median time between the last
surgical procedure and stent implantation was 7.9 years
(range, 3.8-9.2 years; mean, 5.9 1.8 years). Seven patients
had exercise intolerance (with fatigue), 1 had chest pain,
and 1 was asymptomatic.
TABLE 1. Patient data
Patient









1 M TOF, APVS TOF repair  valve implant (2.7) Mitroflow 19 6.5 3.8
2 F TOF, APVS, PAPVD
to SVC
TOF repair (monocusp valve) (0.2), resection of RVOT
and conduit insertion (0.4), conduit revision (1.8),
valve implant (2.2)
Mitroflow 19 6 3.8
3 M TOF, PAPVD to
SVC, LSVC to CS
BTS (0.2), TOF repair (2.5), valve implant and
resection RVOT aneurysm (4.5)
Mitroflow 25 10.3 5.8
4 F TOF, AVSD Total repair  valve implant (2.5) Mitroflow 19 7.9 5.4
5 M TOF, absent LPA BTS (0.1), total repair to RPA with conduit and




6 M Congenital PI/PS,
PDA, ASD
PDA ligation and valve implant (0.02) Mitroflow 19 7.9 7.9
7 F TOF, APVS TOF repair (0.16), valve implant (0.4) Mitroflow 19 5.8 5.4
8 M TOF, APVS TOF repair and valve implant (4.4) Mitroflow 21 9.7 5.3
9 M TGA, VSD, PS Rastelli repair (5.0) and valve implant (8.7) Mitroflow 21 15.2 6.5
TOF, Tetralogy of Fallot; APVS, absent pulmonary valve syndrome; PAPVD, partial anomalous pulmonary venous drainage; SVC, superior vena cava; RVOT,
right ventricular outflow tract; LSVC, left superior vena cava; CS, coronary sinus; BTS, Blalock-Taussing shunt; AVSD, atrioventricular septal defect; LPA,
left pulmonary artery; RPA, right pulmonary artery; PI, pulmonary insufficiency; PS, pulmonary stenosis; PDA, patent ductus arteriosus; ASD, atrial septal
defect; TGA, transposition of the great arteries; VSD, ventricular septal defect.
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On echocardiography, performed at a median of 3
months (range, 0.5-12 months) before the stent procedure,
all patients had significant pulmonary regurgitation (3 mod-
erate and 6 severe), increased RV end-diastolic dimensions
corrected for body surface area (mean, 146%  35%), and
abnormal septal motion with flattening in systole. The mean
peak instantaneous gradient across the valve was 74.7 
15.9 mm Hg (n  9). Tricuspid regurgitation was absent in
2 patients, and trivial or mild regurgitation was present in
the remainder. RV systolic pressure estimate (by velocity of
tricuspid regurgitation jet) was only possible in 5 patients, in
whom the RV/systemic arterial pressure ratio was 0.9 0.2.
Gradients, detected by means of echocardiography (with
patients awake), did not show a correlation with those
obtained by means of catheterization (r  0.1, P  .79).
Mild systolic RV dysfunction (assessed qualitatively) was
present in 3 patients.
Immediate Results
Calcification at the level of the valve leaflets was present in
all implants to variable degrees. In all patients the valve
appeared angiographically to be fixed in a semiopened
position, with reduced mobility and variable degrees of
leaflet fusion to the adjacent wall (Figure 1). There were no
signs of external compression by the sternum or stenosis at
the suture line between the Dacron-pericardial patch exten-
sion and the right ventricle or the main pulmonary artery. A
single P4014 stent (40-mm long) was implanted in 7 pa-
tients, and a single P308 stent (30-mm long) was implanted
in 2 patients. Patient 5 underwent an unsuccessful attempt at
balloon dilation of the bioprosthetic valve with an 18-mm-
diameter balloon before stent implantation.
The right ventricle to pulmonary artery gradient and the
RV/systemic arterial pressure ratio decreased significantly
by 78.9%  11.1% and 49.5%  9.5%, respectively (P 
.001 for both, Table 2). No patient had a final outflow
gradient of greater than 50 mm Hg or an RV systolic
pressure of greater than two thirds of the systemic arterial
pressure. Angiographic diameter of the stenotic region in
the frontal and lateral views increased significantly by sim-
ilar increments (median, 52.8% and 35.4%, respectively;
P  .001; Table 2). Mean fluoroscopy time was 33.1  9.5
minutes (range, 15-42 minutes). Qualitative estimate of RV
systolic function improved immediately after stent implan-
tation in all patients with previous dysfunction, as evi-
denced by improved RV free wall excursion. One patient
had a self-limited episode of Weckenbach atrioventricular
block, and in 1 patient the P4014 stent was not fully ex-
panded after initial implantation with an 18-mm balloon and
required several balloon dilatations before expanding the
stent to 18 mm. There were no significant procedural com-
plications, and in no instance did the stents contact the RV
free wall or cause obstruction to the branch pulmonary
arteries. All patients were discharged home the following
day. There were no complications related to vascular access.
Follow-Up Results
One patient was lost to follow-up. Mean follow-up (visits
included clinical and echocardiographic examination) was
10.9  8.1 months (range, 1-24 months; median, 12
TABLE 2. Immediate results after stent implantation
Before After Change (%) P value




78.9 11.1 .001 (n 8)*




46.6 9.9 .001 (n 9)*




6.9 15.8 .275 (n 9)*




49.5 9.5 .001 (n 9)*




4.7 20.5 .5 (n 9)*




8.0 7.9 .27 (n 8)*














RV, Right ventricle; PA, pulmonary artery; RVp, right ventricular pressure; Sp, systemic arterial pressure; RVedp, right ventricular end-diastolic pressure;
MPAp, main pulmonary artery pressure; AP, anteroposterior; Lat, lateral.
*By t test.
†By Mann-Whitney rank sum test.
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months). Patient 2 had a repeat catheterization 1 year after
the index procedure. RV systolic pressure was 60% of the
systemic arterial pressure during general anesthesia. Even
though there was no localized area of stenosis within the
stent (P308), it was dilated with a 12-mm-diameter balloon,
and no significant increase in stent diameter or decrease in
the RV/systemic pressure ratio occurred. Because it was
believed that the child had outgrown the size of the valve
implant, the patient subsequently underwent an uncompli-
cated pulmonary valve replacement with insertion of a
23-mm Hancock valve (Medtronic, Inc) at the age of 8 years
(14 months after the index stent implantation procedure).
The stent was cut across with heavy scissors, and the valve
was removed by using conventional approaches for valve
replacement.
The 7 other patients available for follow-up reported a
subjective improvement in exercise tolerance and activity
level after stent implantation. On echocardiography at most
recent follow-up, all patients had, as anticipated, free pul-
monary insufficiency, and RV end-diastolic dimensions cor-
rected for body surface area were similar to those before
implantation (mean, 143%  37%; P  .88). Septal flat-
tening in systole disappeared in all patients (P  .001). The
mean peak instantaneous gradient across the valve was
31.7  9.6 mm Hg (n  7), and the RV/systemic arterial
pressure ratio, available in 5 patients, was 0.51  0.12. No
patient had more than mild tricuspid regurgitation. RV
function was qualitatively mildly reduced in 1 patient and
normal in the remaining 6 patients. No endarteritis occurred
in the follow-up period. There were no stent fractures or
embolizations during the follow-up period.
Discussion
The experimental use of balloon expandable stents to re-
lieve obstructions within right heart valved conduits was
first described by Almagor and colleagues.21 Subsequent
clinical studies from this and other institutions have dem-
onstrated the safety and efficacy of this palliative procedure,
postponing the requirement for surgical conduit replace-
ment.15-18,22 However, the role of this palliative approach to
specifically relieve stenosis within a bioprosthetic valve has
not been reviewed.
Differences in the mechanism of late bioprosthetic valve
dysfunction and obstruction within homograft (tissue-
valved) conduits might explain some of the observations in
this study. Calcification and thrombosis of the commissures
result in stenosis by holding the rigid cusps in a semiopened
position, which is a common late finding after valve inser-
tion.23 In addition, valve incompetence caused by thrombo-
sis of the valve sinuses with adherence of the cusp tissue to
the adjacent wall is also frequently present.23 Because of
obscure reasons, calcium deposition with progressive valve
degeneration is more pronounced in children than in adults,
further shortening the longevity of such valves.4-7 Contrary
to these observations in bioprosthetic valves, conduit ob-
struction appears to be due to an internal fibrous peel
formation, with or without concomitant valve stenosis23 or
retraction of the patch extension to the RV free wall. Be-
cause conduits are longer and located in nonanatomic posi-
tions beneath the sternum, they are also more prone to
compression and kinking.16,18,23 In this series calcification
and fixation of the valves in a semiopened position with
reduced mobility and variable degree of fusion of the leaf-
lets to the adjacent wall were demonstrated on angiography
in all patients. The more posterior position of the valve
implant similarly decreases the risk of stent fracture caused
by external compression. Meticulous attention to position-
ing, stent deployment across the area of stenosis at the level
of the leaflets but still within the Dacron or pericardial
extension, and avoidance of stent contact with the heart are
crucial to prevent fractures with subsequent fragment em-
bolization. Additionally, flaring the ends of the stent was not
necessary to secure the stent in a stable position.
Because stenosis within bioprosthetic valves is a more
localized phenomenon,24 stent implantation optimally re-
lieves the obstructive area, reducing the outflow gradient.
As such, the immediate results were good, despite the
presence of calcium deposits within the leaflets or thrombus
within the sinuses. In contrast, results might not be as
satisfactory in conduits affected by a diffuse calcified fi-
brous peeling, external compression, or kinking.16,18
This palliative procedure is not intended as a long-term
solution to the problem of RV outflow tract obstruction. Its
goal is to provide a reliable, safe, easily applied method to
reduce RV pressure, avoiding the requirement of early re-
operation. In this series 1 patient required valve replacement
14 months after the index stent procedure because the child
had outgrown the size of the stent (limited by the diameter
of the bioprosthetic valve implant). Accordingly, from this
experience, in the absence of a discrete lesion within the
stent or a newly acquired more distal obstruction, surgical
replacement is recommended rather than stent redilation.18
The remaining 7 patients continue to be asymptomatic and
benefit from obstruction relief with preserved RV systolic
function and RV systolic pressures of less than 50% of
systemic levels.
Because significant pulmonary insufficiency was already
present in all patients before stent implantation, worsening
of preexisting volume overload was not an issue. In this
regard, RV end-diastolic dimensions have not significantly
increased during follow-up, and free pulmonary insuffi-
ciency in the absence of pressure overload appears to be
well tolerated. Free pulmonary insufficiency is unlikely to
cause RV failure over a short period of time, particularly if
the ventricle has restrictive physiologic characteristics, as is
the case in many postoperative patients with tetralogy of
Fallot.25 However, it might be poorly tolerated if there are
Surgery for Congenital Heart Disease Pedra et al
86 The Journal of Thoracic and Cardiovascular Surgery ● July 2002
CH
D
additional residual lesions, such as distal pulmonary artery
stenoses.26 Therefore accurate angiographic diagnosis and
aggressive treatment of such distal lesions is mandatory at
the time of stent placement.
Although no significant complications occurred in this
series, compression of a coronary artery is a potential prob-
lem that might complicate the procedure, especially when
the underlying anatomy is accompanied by preexisting cor-
onary abnormalities.27 Although this palliative technique
has limited application in the small infant, it might be used
under special circumstances as a rescue measure.28
In conclusion, this review demonstrates the feasibility,
safety, and efficacy of stent implantation across stenotic
bioprosthetic valves in the pulmonary position. The local-
ized obstruction seen at the level of the leaflets, although
fixed and calcified, responds well to stent implantation,
allowing postponement of reoperation with good clinical
tolerance at short-term follow-up.
This study is limited by a small cohort with a relatively
short follow-up period. A larger study involving longer
follow-up and more objective measures of cardiovascular
performance before and after intervention (ie, exercise test-
ing) and measures of RV volumes would also aid in assess-
ing the effect of this palliative strategy on RV function.
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